(Q48744869)

15 February 2018

title

Nomenclature for COX-2 inhibitors (English)

1 reference

15 February 2018

1

J R Vane

1 reference

15 February 2018

author name string

T D Warner

series ordinal

2

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 October 2000

1 reference

15 February 2018

published in

The Lancet

1 reference

15 February 2018

volume

356

1 reference

15 February 2018

issue

9239

1 reference

15 February 2018

page(s)

1373-1374

1 reference

15 February 2018

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902837-3

7 January 2021

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902837-3

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902837-3

7 January 2021

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902837-3

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902837-3

7 January 2021

Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902837-3

7 January 2021

10.1016/S0140-6736(00)02837-3

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018